GlassScriptPhysician profile
Albert F Deloskey
NPI 1891750493
$8,835.29
in general payments reported to CMS, 2019-2025
40 companies · $16.73 in 2025
The $16.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,851 · 2020: $372 · 2021: $428 · 2022: $1,161 · 2023: $2,181 · 2024: $1,827 · 2025: $16.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,023.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,173.49 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $812.01 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $753.66 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $678.52 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $619.99 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $508.08 | 2019-2024 | |
| Pfizer INC. | $479.66 | 2019-2024 | |
| Astellas Pharma US INC | $448.83 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $393.62 | 2019-2024 | Vaxelis, Gardasil 9, Pneumovax 23 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.05 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Exact Sciences Corporation | $318.04 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $310.17 | 2019-2020 | |
| Lilly USA, LLC | $266.26 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $265.19 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $229.55 | 2019-2024 | Otezla, Repatha, Krystexxa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Deloskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.